{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:03:16Z","timestamp":1792612996746,"version":"4.5.0"},"reference-count":37,"publisher":"Harborside Press, LLC","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:p>The NCCN Guidelines for Ovarian Cancer\/Fallopian Tube Cancer\/Primary Peritoneal Cancer provide multidisciplinary diagnostic workup, staging, and treatment recommendations for this disease. These NCCN Guidelines Insights detail how the evolution of the use of PARP inhibitors as maintenance and single-agent regimens for the treatment of ovarian cancer informed panel recommendations in the guidelines.<\/jats:p>","DOI":"10.6004\/jnccn.2024.0052","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T08:47:25Z","timestamp":1729068445000},"page":"512-519","source":"Crossref","is-referenced-by-count":147,"title":["NCCN Guidelines\u00ae Insights: Ovarian Cancer\/Fallopian Tube Cancer\/Primary Peritoneal Cancer, Version 3.2024"],"prefix":"10.6004","volume":"22","author":[{"given":"Joyce","family":"Liu","sequence":"first","affiliation":[{"name":"Dana-Farber\/Brigham and Women\u2019s Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Berchuck","sequence":"additional","affiliation":[{"name":"Duke Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floor J.","family":"Backes","sequence":"additional","affiliation":[{"name":"The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Cohen","sequence":"additional","affiliation":[{"name":"City of Hope National Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Grisham","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A.","family":"Leath","sequence":"additional","affiliation":[{"name":"O\u2019Neal Comprehensive Cancer Center at UAB"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lainie","family":"Martin","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center at the University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Matei","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Miller","sequence":"additional","affiliation":[{"name":"UT Southwestern Simmons Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Robertson","sequence":"additional","affiliation":[{"name":"Indiana University Melvin and Bren Simon Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Barroilhet","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shitanshu","family":"Uppal","sequence":"additional","affiliation":[{"name":"University of Michigan Rogel Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Wahner","family":"Hendrickson","sequence":"additional","affiliation":[{"name":"Mayo Clinic Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Gershenson","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi J.","family":"Gray","sequence":"additional","affiliation":[{"name":"Fred Hutch Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ardeshir","family":"Hakam","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Jain","sequence":"additional","affiliation":[{"name":"Fox Chase Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gottfried E.","family":"Konecny","sequence":"additional","affiliation":[{"name":"UCLA Jonsson Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Moroney","sequence":"additional","affiliation":[{"name":"The UChicago Medicine Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Ratner","sequence":"additional","affiliation":[{"name":"Yale Cancer Center\/Smilow Cancer Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Schorge","sequence":"additional","affiliation":[{"name":"St. Jude Children\u2019s Research Hospital\/The University of Tennessee Health Science Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Premal H.","family":"Thaker","sequence":"additional","affiliation":[{"name":"Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa L.","family":"Werner","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute at the University of Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emese","family":"Zsiros","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kian","family":"Behbakht","sequence":"additional","affiliation":[{"name":"University of Colorado Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee-May","family":"Chen","sequence":"additional","affiliation":[{"name":"UCSF Helen Diller Family Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"DeRosa","sequence":"additional","affiliation":[{"name":"Patient Advocate"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric L.","family":"Eisenhauer","sequence":"additional","affiliation":[{"name":"Mass General Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Leiserowitz","sequence":"additional","affiliation":[{"name":"UC Davis Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babak","family":"Litkouhi","sequence":"additional","affiliation":[{"name":"Stanford Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"McHale","sequence":"additional","affiliation":[{"name":"UC San Diego Moores Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanja","family":"Percac-Lima","sequence":"additional","affiliation":[{"name":"Mass General Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry","family":"Rodabaugh","sequence":"additional","affiliation":[{"name":"Fred & Pamela Buffett Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Vargas","sequence":"additional","affiliation":[{"name":"Case Comprehensive Cancer Center\/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frankie","family":"Jones","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Kovach","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Hang","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swathi","family":"Ramakrishnan","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald D.","family":"Alvarez","sequence":"additional","affiliation":[{"name":"Vanderbilt-Ingram Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah K.","family":"Armstrong","sequence":"additional","affiliation":[{"name":"Johns Hopkins Kimmel Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","series-title":"CA Cancer J Clin","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel RL","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin 2024;74:12\u201349."},{"key":"B2","series-title":"J Clin Oncol","first-page":"2654","article-title":"BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group","volume":"30","author":"Alsop K","year":"2012","unstructured":"Alsop K, Fereday S, Meldrum C,  BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol 2012;30:2654\u20132663."},{"key":"B3","series-title":"Nature","first-page":"609","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","year":"2011","unstructured":"Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609\u2013615."},{"key":"B4","series-title":"EMBO J","first-page":"4704","article-title":"Mutation in BRCA2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences","volume":"20","author":"Tutt A","year":"2001","unstructured":"Tutt A, Bertwistle D, Valentine J,  Mutation in BRCA2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences. EMBO J 2001;20:4704\u20134716."},{"key":"B5","series-title":"Mol Cell","first-page":"511","article-title":"BRCA1 controls homology-directed DNA repair","volume":"4","author":"Moynahan ME","year":"1999","unstructured":"Moynahan ME, Chiu JW, Koller BH, Jasin M. BRCA1 controls homology-directed DNA repair. Mol Cell 1999;4:511\u2013518."},{"key":"B6","series-title":"Ann Oncol","first-page":"32","article-title":"PARP inhibitors for BRCA1\/2 mutation-associated and BRCA-like malignancies","volume":"25","author":"Lee JM","year":"2014","unstructured":"Lee JM, Ledermann JA, Kohn EC. PARP inhibitors for BRCA1\/2 mutation-associated and BRCA-like malignancies. Ann Oncol 2014;25:32\u201340."},{"key":"B7","series-title":"N Engl J Med","first-page":"2495","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore K","year":"2018","unstructured":"Moore K, Colombo N, Scambia G,  Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2018;379:2495\u20132505."},{"key":"B8","series-title":"Ann Oncol","first-page":"S613","article-title":"811MO Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f\/u) from SOLO1","volume":"31","author":"Banerjee S","year":"2020","unstructured":"Banerjee S, Moore KN, Colombo N,  811MO Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f\/u) from SOLO1. Ann Oncol 2020;31:S613."},{"key":"B9","series-title":"J Clin Oncol","first-page":"609","article-title":"Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1\/GOG 3004 trial","volume":"41","author":"DiSilvestro P","year":"2023","unstructured":"DiSilvestro P, Banerjee S, Colombo N,  Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1\/GOG 3004 trial. J Clin Oncol 2023;41:609\u2013617."},{"key":"B10","series-title":"Ann Oncol","first-page":"681","article-title":"Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial","volume":"34","author":"Ray-Coquard I","year":"2023","unstructured":"Ray-Coquard I, Leary A, Pignata S,  Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial. Ann Oncol 2023;34:681\u2013692."},{"key":"B11","series-title":"N Engl J Med","first-page":"2391","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonzalez-Martin A","year":"2019","unstructured":"Gonzalez-Martin A, Pothuri B, Vergote I,  Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2019;381:2391\u20132402."},{"key":"B12","series-title":"Ann Oncol","article-title":"Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from PRIMA\/ENGOT-OV26\/GOG-3012 trial","author":"Monk BJ","unstructured":"Monk BJ, Barretina-Ginesta MP, Pothuri B,  Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from PRIMA\/ENGOT-OV26\/GOG-3012 trial. Ann Oncol. Published online August 21, 2024. doi:10.1016\/j.annonc.2024.08.2241"},{"key":"B13","series-title":"J Clin Oncol","first-page":"3952","article-title":"A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO\/GOG-3020\/ENGOT-ov45)","volume":"40","author":"Monk BJ","year":"2022","unstructured":"Monk BJ, Parkinson C, Lim MC,  A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO\/GOG-3020\/ENGOT-ov45). J Clin Oncol 2022;40:3952\u20133964."},{"key":"B14","series-title":"Gynecol Oncol","first-page":"404","article-title":"Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma","volume":"167","author":"O\u2019Malley DM","year":"2022","unstructured":"O\u2019Malley DM, Oza AM, Lorusso D,  Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma. Gynecol Oncol 2022;167:404\u2013413."},{"key":"B15","series-title":"Gynecol Oncol","first-page":"219","article-title":"OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab","volume":"166","author":"Hardesty MM","year":"2022","unstructured":"Hardesty MM, Krivak TC, Wright GS,  OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab. Gynecol Oncol 2022;166:219\u2013229."},{"key":"B16","series-title":"Oncologist","first-page":"e164","article-title":"FDA approval summary: olaparib monotherapy or in combination with bevacizumab for the maintenance treatment of patients with advanced ovarian cancer","volume":"26","author":"Arora S","year":"2021","unstructured":"Arora S, Balasubramaniam S, Zhang H,  FDA approval summary: olaparib monotherapy or in combination with bevacizumab for the maintenance treatment of patients with advanced ovarian cancer. Oncologist 2021;26:e164\u2013172."},{"key":"B17","article-title":"FDA approves niraparib for first-line maintenance of advanced ovarian cancer","unstructured":"US Food & Drug Administration. FDA approves niraparib for first-line maintenance of advanced ovarian cancer. Accessed December 9, 2022. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-niraparib-first-line-maintenance-advanced-ovarian-cancer"},{"key":"B18","article-title":"FDA approves rucaparib for maintenance treatment of recurrent ovarian, fallopian tube, or primary peritoneal cancer","unstructured":"US Food & Drug Administration. FDA approves rucaparib for maintenance treatment of recurrent ovarian, fallopian tube, or primary peritoneal cancer. Accessed December 9, 2022. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-rucaparib-maintenance-treatment-recurrent-ovarian-fallopian-tube-or-primary-peritoneal"},{"key":"B19","series-title":"Lancet Oncol","first-page":"852","article-title":"Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study","volume":"12","author":"Gelmon KA","year":"2011","unstructured":"Gelmon KA, Tischkowitz M, Mackay H,  Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011;12:852\u2013861."},{"key":"B20","series-title":"Lancet","first-page":"245","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial","volume":"376","author":"Audeh MW","year":"2010","unstructured":"Audeh MW, Carmichael J, Penson RT,  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010;376:245\u2013251."},{"key":"B21","series-title":"J Clin Oncol","first-page":"2512","article-title":"Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval","volume":"28","author":"Fong PC","year":"2010","unstructured":"Fong PC, Yap TA, Boss DS,  Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010;28:2512\u20132519."},{"key":"B22","series-title":"Drugs","first-page":"231","article-title":"Olaparib: first global approval","volume":"75","author":"Deeks ED.","year":"2015","unstructured":"Deeks ED. Olaparib: first global approval. Drugs 2015;75:231\u2013240."},{"key":"B23","series-title":"Clin Cancer Res","first-page":"4257","article-title":"FDA approval summary: olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy","volume":"21","author":"Kim G","year":"2015","unstructured":"Kim G, Ison G, McKee AE,  FDA approval summary: olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy. Clin Cancer Res 2015;21:4257\u20134261."},{"key":"B24","series-title":"Lancet Oncol","first-page":"75","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial","volume":"18","author":"Swisher EM","year":"2017","unstructured":"Swisher EM, Lin KK, Oza AM,  Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol 2017;18:75\u201387."},{"key":"B25","series-title":"Clin Cancer Res","first-page":"7165","article-title":"FDA approval summary: rucaparib for the treatment of patients with deleterious BRCA mutation-associated advanced ovarian cancer","volume":"23","author":"Balasubramaniam S","year":"2017","unstructured":"Balasubramaniam S, Beaver JA, Horton S,  FDA approval summary: rucaparib for the treatment of patients with deleterious BRCA mutation-associated advanced ovarian cancer. Clin Cancer Res 2017;23:7165\u20137170."},{"key":"B26","series-title":"N Engl J Med","first-page":"2154","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza MR","year":"2016","unstructured":"Mirza MR, Monk BJ, Herrstedt J,  Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 2016;375:2154\u20132164."},{"key":"B27","series-title":"Lancet Oncol","first-page":"465","article-title":"Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial","volume":"23","author":"Kristeleit R","year":"2022","unstructured":"Kristeleit R, Lisyanskaya A, Fedenko A,  Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial. Lancet Oncol 2022;23:465\u2013478."},{"key":"B28","series-title":"Clin Cancer Res","first-page":"4095","article-title":"A phase I-II study of the oral PARP inhibitor rucaparib in patients with germline BRCA1\/2-mutated ovarian carcinoma or other solid tumors","volume":"23","author":"Kristeleit R","year":"2017","unstructured":"Kristeleit R, Shapiro GI, Burris HA,  A phase I-II study of the oral PARP inhibitor rucaparib in patients with germline BRCA1\/2-mutated ovarian carcinoma or other solid tumors. Clin Cancer Res 2017;23:4095\u20134106."},{"key":"B29","article-title":"Important Prescribing Information: rucaparib for treatment of BRCA- mutated ovarian cancer after 2 or more chemotherapies is voluntarily withdrawn in the US","unstructured":"Important Prescribing Information: rucaparib for treatment of BRCA- mutated ovarian cancer after 2 or more chemotherapies is voluntarily withdrawn in the US. Accessed August 22, 2022. Available at: https:\/\/clovisoncology.com\/pdfs\/US_DHCPL_final_signed.pdf"},{"key":"B30","series-title":"J Clin Oncol","first-page":"244","article-title":"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation","volume":"33","author":"Kaufman B","year":"2015","unstructured":"Kaufman B, Shapira-Frommer R, Schmutzler RK,  Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation. J Clin Oncol 2015;33:244\u2013250."},{"key":"B31","series-title":"J Clin Oncol","first-page":"1164","article-title":"Olaparib versus nonplatinum chemotherapy in patients with platinum-sensitive relapsed ovarian cancer and a germline BRCA1\/2 mutation (SOLO3): a randomized phase III trial","volume":"38","author":"Penson RT","year":"2020","unstructured":"Penson RT, Valencia RV, Cibula D,  Olaparib versus nonplatinum chemotherapy in patients with platinum-sensitive relapsed ovarian cancer and a germline BRCA1\/2 mutation (SOLO3): a randomized phase III trial. J Clin Oncol 2020;38:1164\u20131174."},{"key":"B32","series-title":"Gynecol Oncol","first-page":"S19","article-title":"Final overall survival results from SOLO3: phase III trial assessing olaparib monotherapy versus non-platinum chemotherapy in heavily pretreated patients with germline BRCA1 - and\/or BRCA2-mutated platinum-sensitive relapsed ovarian cancer (026)","volume":"166","author":"Penson R","year":"2022","unstructured":"Penson R, Valencia RV, Colombo N,  Final overall survival results from SOLO3: phase III trial assessing olaparib monotherapy versus non-platinum chemotherapy in heavily pretreated patients with germline BRCA1 - and\/or BRCA2-mutated platinum-sensitive relapsed ovarian cancer (026). Gynecol Oncol 2022;166:S19\u201320."},{"key":"B33","article-title":"Dear Health Care Provider Letter (Olaparib) - September 2023","unstructured":"AstraZeneca. Dear Health Care Provider Letter (Olaparib) - September 2023. Accessed December 9, 2022. Available at: https:\/\/www.lynparzahcp.com\/content\/dam\/physician-services\/us\/590-lynparza-hcp-branded\/hcp-global\/pdf\/solo3-dhcp-final-signed.pdf"},{"key":"B34","article-title":"Dear Health Care Provider Letter (Niraparib) - November 2022","unstructured":"GSK. Dear Health Care Provider Letter (Niraparib) - November 2022. Accessed December 9, 2022. Available at: https:\/\/www.zejulahcp.com\/content\/dam\/cf-pharma\/hcp-zejulahcp-v2\/en_US\/pdf\/ZEJULA%20(niraparib)%20Dear%20HCP%20Letter%20November%202022.pdf"},{"key":"B35","series-title":"Lancet Haematol","first-page":"e122","article-title":"Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database","volume":"8","author":"Morice PM","year":"2021","unstructured":"Morice PM, Leary A, Dolladille C,  Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database. Lancet Haematol 2021;8:e122\u2013134."},{"key":"B36","series-title":"Lancet Oncol","first-page":"620","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Poveda A","year":"2021","unstructured":"Poveda A, Floquet A, Ledermann JA,  Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2021;22:620\u2013631."},{"key":"B37","series-title":"Int J Gynecol Cancer","first-page":"A3","article-title":"O003\/#557 Overall survival results from ARIEL3: a phase 3 randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma","volume":"32","author":"Coleman RL","year":"2022","unstructured":"Coleman RL, Oza A, Lorusso D,  O003\/#557 Overall survival results from ARIEL3: a phase 3 randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma. Int J Gynecol Cancer 2022;32:A3\u20134."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/22\/8\/article-p512.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/22\/8\/article-p512.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/22\/8\/article-p512.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T08:47:26Z","timestamp":1729068446000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/22\/8\/article-p512.xml"}},"subtitle":["Featured Updates to the NCCN Guidelines"],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":37,"journal-issue":{"issue":"8"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2024.0052","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10]]}}}